The destruction of foreign or abnormally altered cells by T cells is a core component of immune defense, but some tumor cells have developed ways to escape immune surveillance and can therefore not be attacked by T cells. Affimed’s T cell engagers are designed to unmask the tumor cells and enable T cells to recognize and killed the tumor cells .
Redirecting T cells to fight cancer
Targets CD19 on tumor cells and CD3 on T cells
AFM11 is a tetravalent, bispecific T cell engager that is being developed in non-Hodgkin lymphoma (NHL) and in acute lymphoblastic leukemia (ALL).
Targets CD33 on tumor cells and CD3 on T cells
AMV564 is a tetravalent, bispecific T cell engager derived from Affimed’s technology platform that is being developed by Amphivena in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).